Evofem Biosciences, Inc.
Hedge Funds Holdings
Last updated:
Evofem Biosciences, Inc.‘s stocks are currently a part of 31 hedge funds’ portfolios, which represents 100% of the total amount of its stocks outstanding. This makes up a total of 7.60M shares of Evofem Biosciences, Inc.. Compared to the previous quarter, the number grew by 479.68% or 6.29M shares more. As for the holding position changes, 9.68% (3) of current hedge fund investors increased the number of shares held, and 161.29% (50) closed the holdings completely. 29 hedge funds are new holders of Evofem Biosciences, Inc. stock in Q2 2022, it is 93.55% of total holders.
Hedge funds holding Evofem Biosciences (Q1 2018 – Q2 2022)
Q1 2018 | 11 |
---|---|
Q2 2018 | 12 |
Q3 2018 | 15 |
Q4 2018 | 14 |
Q1 2019 | 16 |
Q2 2019 | 35 |
Q3 2019 | 41 |
Q4 2019 | 41 |
Q1 2020 | 50 |
Q2 2020 | 104 |
Q3 2020 | 85 |
Q4 2020 | 82 |
Q1 2021 | 93 |
Q2 2021 | 70 |
Q3 2021 | 60 |
Q4 2021 | 48 |
Q1 2022 | 52 |
Q2 2022 | 31 |
Hedge funds changes in Evofem Biosciences positions (Q1 2018 – Q2 2022)
Q1 2018 | 11 | 0 | 0 | 0 | 0 |
---|---|---|---|---|---|
Q2 2018 | 5 | 6 | 0 | 3 | -2 |
Q3 2018 | 6 | 2 | 2 | 3 | 2 |
Q4 2018 | 0 | 6 | 3 | 1 | 4 |
Q1 2019 | 2 | 6 | 5 | 0 | 3 |
Q2 2019 | 23 | 9 | 3 | 4 | -4 |
Q3 2019 | 10 | 13 | 9 | 4 | 5 |
Q4 2019 | 7 | 15 | 9 | 6 | 4 |
Q1 2020 | 11 | 12 | 18 | 2 | 7 |
Q2 2020 | 59 | 37 | 6 | 4 | -2 |
Q3 2020 | 13 | 37 | 24 | 31 | -20 |
Q4 2020 | 18 | 29 | 20 | 20 | -5 |
Q1 2021 | 29 | 31 | 20 | 16 | -3 |
Q2 2021 | 15 | 21 | 23 | 40 | -29 |
Q3 2021 | 11 | 12 | 18 | 21 | -2 |
Q4 2021 | 5 | 11 | 14 | 17 | 1 |
Q1 2022 | 11 | 11 | 15 | 6 | 9 |
Q2 2022 | 29 | 3 | 0 | 50 | -51 |
Hedge funds changes in Evofem Biosciences stock options (Q1 2018 – Q2 2022)
Q1 2018 | 0 | 0 |
---|---|---|
Q2 2018 | 271,000 | 0 |
Q3 2018 | 405,000 | 0 |
Q4 2018 | 419,000 | 0 |
Q1 2019 | 350,000 | 0 |
Q2 2019 | 664,000 | 0 |
Q3 2019 | 504,000 | 0 |
Q4 2019 | 617,000 | 0 |
Q1 2020 | 585,000 | 0 |
Q2 2020 | 1,299,000 | 809,000 |
Q3 2020 | 1,099,000 | 1,241,000 |
Q4 2020 | 2,161,000 | 1,652,000 |
Q1 2021 | 1,050,000 | 1,217,000 |
Q2 2021 | 2,941,000 | 1,291,000 |
Q3 2021 | 6,000,002,038,000 | 611,000 |
Q4 2021 | 2,000,000,961,000 | 285,000 |
Q1 2022 | 714,000 | 143,000 |
Q2 2022 | 3,827,000 | 1,176,000 |